<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Biol Ther</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Biol. Ther</journal-id><journal-id journal-id-type="publisher-id">KCBT</journal-id><journal-id journal-id-type="publisher-id">kcbt20</journal-id><journal-title-group><journal-title>Cancer Biology &amp; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1538-4047</issn><issn pub-type="epub">1555-8576</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6301798</article-id><article-id pub-id-type="publisher-id">1491501</article-id><article-id pub-id-type="doi">10.1080/15384047.2018.1491501</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma</article-title><alt-title alt-title-type="running-authors">J.-J. YAO ET AL.</alt-title><alt-title alt-title-type="running-title">CANCER BIOLOGY &amp; THERAPY</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yao</surname><given-names>Ji-Jin</given-names></name><xref ref-type="aff" rid="AFF0001"><sup>a</sup></xref><xref ref-type="aff" rid="AFF0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lu-Lu</given-names></name><xref ref-type="aff" rid="AFF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Tian-Sheng</given-names></name><xref ref-type="aff" rid="AFF0003"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Ying-Lin</given-names></name><xref ref-type="aff" rid="AFF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lawrence</surname><given-names>Wayne R.</given-names></name><xref ref-type="aff" rid="AFF0004"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Wang-Jian</given-names></name><xref ref-type="aff" rid="AFF0004"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Fan</given-names></name><xref ref-type="aff" rid="AFF0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Guan-Qun</given-names></name><xref ref-type="aff" rid="AFF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Si-Yang</given-names></name><xref ref-type="aff" rid="AFF0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Ying</given-names></name><xref ref-type="corresp" rid="AN0001"/><xref ref-type="aff" rid="AFF0001"><sup>a</sup></xref></contrib><aff id="AFF0001"><label>a</label><institution>Department of Radiation Oncology, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology</institution>, Guangzhou, Guangdong Province, <country>P.R. China</country></aff><aff id="AFF0002"><label>b</label><institution>Department of Radiation Oncology, the Fifth Affiliated Hospital of Sun Yat-sen University</institution>, Zhuhai Guangdong Province, <country>P.R. China</country></aff><aff id="AFF0003"><label>c</label><institution>Department of Radiation Oncology, Wuzhou Red Cross Hospital</institution>, Wuzhou, Guangxi Province, <country>People&#8217;s Republic of China</country></aff><aff id="AFF0004"><label>d</label><institution>Department of Environmental Health Sciences, School of Public Health, University, Albany, State University of New York</institution>, Rensselaer, NY, <country>USA</country></aff></contrib-group><author-notes><corresp id="AN0001">CONTACT Ying Sun, Ph.D, <email xlink:href="sunying@sysucc.org.cn">sunying@sysucc.org.cn</email><institution>Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy</institution>, Guangzhou 510060, Guangdong Province, <country>China</country></corresp><fn><p>Ji-Jin Yao, Lu-Lu Zhang and Tian-Sheng Gao contributed equally to this work.</p></fn><fn><p>Color versions of one or more of the figures in the article can be found online at <ext-link ext-link-type="uri" xlink:href="http://www.tandfonline.com/kcbt">www.tandfonline.com/kcbt</ext-link>.</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>6</day><month>8</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>8</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>19</volume><issue>12</issue><fpage seq="6">1102</fpage><lpage>1107</lpage><history><date date-type="received"><day>26</day><month>3</month><year>2018</year></date><date date-type="rev-recd"><day>26</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>17</day><month>6</month><year>2018</year></date></history><permissions><copyright-statement>&#169; 2018 The Author(s). Published by Taylor &amp; Francis.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="kcbt-19-12-1491501.pdf"/><abstract><title>ABSTRACT</title><p><bold>Purpose</bold>: The benefits of additional use of nimotuzumab (NTZ) in the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC) is largely unclear. We aim to compare LA-NPC treatment outcomes in patients that received CCRT with nimotuzumab (NTZ) to patients that received CCRT only.</p><p><bold>Materials and Methods</bold>: Between October 2009 and January 2012, 31 previously untreated and newly diagnosed LA-NPC patients were administered CCRT (3 cycles of 100&#160;mg/m<sup>2</sup> cisplatin every third week with intensity-modulated radiotherapy) plus NTZ according to an IRB-approved institutional research protocol. A well-balanced cohort of 62 patients who received CCRT alone was created by matching each patient who received CCRT plus NTZ via propensity-matched analysis in a 2:1 ratio.</p><p><bold>Results</bold>: Compared with CCRT only, CCRT plus NTZ was significantly associated with superior overall survival (5-year OS; 96.8% vs. 82.3%; <italic>P&#160;</italic>=&#160;0.001), superior distant metastasis-free survival (5-year DMFS; 90.3% vs. 80.6%, <italic>P&#160;</italic>=&#160;0.012) and superior progression-free survival (5-year PFS; 83.9% vs. 71.0%, <italic>P&#160;</italic>=&#160;0.006). In multivariate analysis, the inclusion of NTZ to CCRT was confirmed to be a favorable factor for OS (HR, 0.31; 95% CI, 0.02&#8211;0.71; <italic>P&#160;</italic>=&#160;0.027), DMFS (HR, 0.45; 95% CI, 0.13&#8211;0.77; <italic>P&#160;</italic>=&#160;0.034), and PFS (HR, 0.38; 95% CI, 0.11&#8211;0.89; <italic>P&#160;</italic>=&#160;0.041). In addition, no significant differences in hematology parameters, dermatitis, nausea, vomiting, xerostomia, nephrotoxicity or neurotoxicity were found between the two arms (all <italic>P</italic>&#160;&gt;&#160;0.05).</p><p><bold>Conclusion</bold>: The inclusion of NTZ to CCRT is more effective for long-term survival among LA-NPC patients than CCRT only.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Nasopharyngeal carcinoma</kwd><kwd>nimotuzumab</kwd><kwd>propensity score matching</kwd><kwd>concurrent chemoradiotherapy</kwd><kwd>survival</kwd><kwd>acute toxicity</kwd><kwd>locoregionally</kwd></kwd-group><funding-group><award-group><funding-source><named-content content-type="funder-name">the Health &amp; Medical Collaborative Innovation Project of Guangzhou City, China</named-content></funding-source><award-id>201604020003</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">the Special Support Program of Sun Yat-sen University Cancer Center</named-content></funding-source><award-id>16zxtzlc06</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">the Planned Science and Technology Project of Guangdong Province</named-content></funding-source><award-id>20160307</award-id></award-group><funding-statement>This work was supported by the the Health &amp; Medical Collaborative Innovation Project of Guangzhou City, China [201604020003]; the Special Support Program of Sun Yat-sen University Cancer Center [16zxtzlc06]; the Planned Science and Technology Project of Guangdong Province [20160307]; and the Special Support Program of Sun Yat-sen University Cancer Center (16zxtzlc06).</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="3"/><ref-count count="29"/><page-count count="6"/></counts></article-meta></front><body><sec sec-type="intro" id="S0001"><title>Introduction</title><p>Nasopharyngeal carcinoma (NPC) is a relatively rare head and neck tumor in North America and Europe,<sup><xref rid="CIT0001">1</xref></sup>&#160;however, endemic in southern China.<sup><xref rid="CIT0002">2</xref></sup> Prior studies reported that<sup><xref rid="CIT0003">3</xref></sup> up to 70% of NPC patients are diagnosed with locoregionally advanced (Stage III-IVB) NPC at presentation. Based on guidelines set by the National Comprehensive Cancer Network (NCCN), treatment standards for locoregionally advanced NPC (LA-NPC) is concurrent chemoradiotherapy (CCRT).<sup><xref rid="CIT0004">4</xref></sup> However, for approximately thirty percent of NPC patients, this therapy can be ineffective, as majority of these failures in treatment are because of distant metastasis.<sup><xref rid="CIT0005">5</xref>,<xref rid="CIT0006">6</xref></sup> Thus, novel treatment strategies are needed for further improvement in outcomes of patients with LA-NPC.</p><p>In most human epithelial carcinomas, epidermal growth factor receptor (EGFR) is greatly expressed, and has shown to correlate with poor prognosis.<sup><xref rid="CIT0007">7</xref>,<xref rid="CIT0008">8</xref></sup> Moreover, previous studies have reported that EGFR is overexpressed in 80% of NPC patients,<sup><xref rid="CIT0009">9</xref></sup> and has potential promise for new therapeutic target in NPC patients. Ideally, addition of EGFR-targeting antibody to the standard CCRT regimen could improve the outcomes of patients with NPC. However, the RTOG 0522 study<sup><xref rid="CIT0010">10</xref></sup> showed the combination of cetuximab (the first EGFR-targeting antibody to be approved by United States Food and Drug Administration) with CCRT cannot be recommended for head and neck carcinoma (not included NPC), as this regimen increased acute toxicities without improving survival outcomes. Nimotuzumab (NTZ) is another EGFR-targeting antibody that does not exert intrinsic stimulating activity.<sup><xref rid="CIT0011">11</xref></sup> A phase II trial found the addition of NTZ to CCRT was associated with encouraging survival outcomes in LA-NPC, though only 23 patients were enrolled to be administered CCRT and NTZ, with a follow-up median of 24.1&#160;months.<sup><xref rid="CIT0012">12</xref></sup> Considering the absence of randomized controlled trial to determine the efficacy of CCRT plus NTZ vs. CCRT alone in patients with LA-NPC, it remains under debate if patients with LA-NPC benefit from the addition of NTZ for the recommended standard treatment of CCRT.</p><p>To address this knowledge gap, we reviewed data on 93 patients with LA-NPC who received the standard CCRT regimen with or without NTZ to provide additional information on the benefit of NTZ in the treatment of LA-NPC.</p></sec><sec id="S0002"><title>Materials and methods</title><sec id="S0002-S2001"><title>Patients</title><p>Between October 2009 and January 2012, patients with histologically-confirmed NPC treated at Sun Yat-sen University Cancer Center were retrospectively reviewed. All included patients had to meet the following inclusion criteria: (1) disease classified as stage III-IVB in accordance to the American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) staging system (7th edition, 2009); (2) histologically confirmed NPC; (3) patient received the standard CCRT regimen with or without NTZ; (4) radiation delivery technique was intensity-modulated radiotherapy (IMRT); (5) molecularly-targeted drug was NTZ.</p></sec><sec id="S0002-S2002"><title>Treatment</title><p>IMRT treatment details have been previously reported.<sup><xref rid="CIT0013">13</xref></sup> Target volumes were delineated according to a previously described treatment protocol by our institution,<sup><xref rid="CIT0012">12</xref></sup> in agreement with International Commission on Radiation Units (ICRU) and Measurements reports 62<sup><xref rid="CIT0014">14</xref></sup> and 83.<sup><xref rid="CIT0015">15</xref></sup> The prescribed radiation dose was defined as follows: a total dose of 68&#8211;70&#160;Gy at 2.12&#8211;2.27&#160;Gy/fraction to the planning target volume (PTV) of the GTV-P (primary gross tumor volume), 60&#160;Gy to the PTV of CTV-1 (high-risk regions) and 54&#160;Gy to the PTV of CTV-2 (low-risk regions). All patients were treated with one fraction daily, five days per week. Concomitant chemotherapy consisted of cisplatin (100&#160;mg/m<sup>2</sup>) every three weeks, or cisplatin (40&#160;mg/m<sup>2</sup>) weekly. Reasons for non-compliance included refusal by individual patients, age, or organ dysfunction suggestive of intolerance. NTZ was administered concomitantly with IMRT at a dose of 200&#160;mg weekly, commencing on the first day of radiotherapy. NTZ was diluted in 250&#160;mL saline and intravenously infused over 1 h.</p></sec><sec id="S0002-S2003"><title>Ethical statement</title><p>This study was approved by our institutional review board (IRB-approved number, YB2017-040). As this was a retrospective analysis of routine clinical data, a waiver of the requirement for individual informed consent was granted by the institutional ethics committee.</p></sec><sec id="S0002-S2004"><title>Follow-up</title><p>During treatment, evaluation of patients occurred at least one time a week. After treatment, patients were evaluated every third month during the first three years, every six months the following two years, and every year afterward. During this period, for each follow-up visit, patients underwent a sequence of conventional examinations to detect potential relapse or distant metastasis. Biopsy, MRI (magnetic resonance imaging), or both was used to confirm local relapse. Clinical examination and MRI of the neck was used to diagnosis regional relapse, and in doubtful cases, by fine needle aspiration of lymph nodes. To diagnosis distant metastasis, physical examinations, clinical symptoms, and imaging methods with bone scan, chest radiography, abdominal sonography, and MRI was used. Further investigations were arranged if indicated.</p></sec><sec id="S0002-S2005"><title>Statistical analysis</title><p>We used propensity score matching method to select patients treated with CCRT plus NTZ to match with CCRT treatment only.<sup><xref rid="CIT0016">16</xref></sup> According to presumed covariates, including age, Karnofsky score, pathology, total radiation dose, sex, chemotherapy, T category, N category and clinical stage, logistic regression was computed for each patient for propensity scores. At a 1:2 ratio, we matched patients without replacement using these scores, instead of by individual covariates.</p><p>Using &#967;<sup>2</sup> test, the balance of covariates between both study arms were examined. Kaplan-Meier method was used to estimate overall survival (OS), distant metastasis-free survival (DMFS), progression-free survival (PFS), locoregional relapse-free survival (LRRFS).<sup><xref rid="CIT0017">17</xref></sup> Cox regression analysis was used to calculate both crude and adjusted hazard ratios with 95% confidence intervals (for CCRT plus NTZ, using CCRT as the reference).<sup><xref rid="CIT0018">18</xref></sup> All test were two-tailed and P values &lt;&#160;0.05 were deemed statistically significant. We performed all analyses using R 3.1.2 software (Vienna, Austria; <ext-link ext-link-type="uri" xlink:href="https://mirrors.tuna.singhua">https://mirrors.tuna.singhua</ext-link>. edu.cn/CRAN/).</p></sec></sec><sec id="S0003"><title>Results</title><sec id="S0003-S2001"><title>Patient characteristics</title><p>31 patients treated with CCRT plus NTZ and 62 patients treated with CCRT only remained in the current analysis after propensity score matching. The follow-up median was 59.2&#160;months (49.5&#8211;72.4&#160;months) for the CCRT plus NTZ arm and 57.4&#160;months (6.5&#8211;69.4&#160;months) for the CCRT only arm. In the CCRT plus NTZ arm, 3 (9.7%) patients suffered distant metastasis, and 4 patients (12.9%) developed locoregional recurrence. In the CCRT only arm, 13 (21.0%) patients suffered distant metastasis, and 7 patients (11.3%) developed locoregional recurrence. Interestingly, only 33% (2/6) patients suffered disease progression within 3&#160;years after radical RT in the CCRT plus NTZ arm. In contrast, up to 90% (16/18) patients suffered disease progression within 3&#160;years after radical RT the CCRT only arm. <xref rid="T0001">Table 1</xref> presents the characteristics at baseline for the two study arms. We did not observe a significant difference in respect to age, pathology, sex, Karnofsky score, total radiation dose, radiotherapy treatment time, chemotherapy, T category, N category and overall stage. Subsequent analyses reported derived from propensity-matched cohort.<table-wrap id="T0001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1080/15384047.2018.1491501-T0001</object-id><label>Table 1.</label><caption><p>Patient and tumor characteristics.</p></caption><!--OASIS TABLE HERE--><table-wrap-foot><fn><p><bold>Abbreviations</bold>: WHO, World Health Organization; CCRT, Concurrent chemoradiotherapy; CRT, Concurrent chemotherapy; NS, not significant. RTT, Radiotherapy treatment time.</p><p>* CCRT plus nimotuzumab vs. CCRT; chi-square or Fisher&#8217;s exact tests.</p><p><sup>&#167;</sup> The 7th American Joint Commission on Cancer staging system.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="S0003-S2002"><title>Treatment and compliance</title><p>All patients completed the full course of radiotherapy. In the CCRT plus NTZ arm, 2/31 patients (6.5%) completed four cycles of NTZ, 5 (16.1%) completed five cycles, 21 (67.7%) completed six cycles, and 3 (9.7%) completed seven cycles. 21 of the 31 patients (67.7%) received two or three cycles of 100&#160;mg/m<sup>2</sup> cisplatin each third week, and 10 (32.3%) received 40&#160;mg/m<sup>2</sup> cisplatin weekly for 5&#8211;7 planned cycles. Median administered total dose of cisplatin during radiotherapy was 240&#160;mg/m<sup>2</sup> (IQR 200&#8211;280&#160;mg/m<sup>2</sup>) in the CCRT plus NTZ arm. As shown in <xref rid="T0001">Table 1</xref>, propensity score matching ensured the chemotherapy regimens and cycles of the CCRT only arm were well-matched with those of the CCRT plus NTZ arm.</p></sec><sec id="S0003-S2003"><title>Survival outcomes and multivariate analysis</title><p>The differences in efficacy between these two arms are presented in <xref rid="F0001">Figure 1</xref>. The 5-year OS was significantly higher for CCRT plus NTZ than those treated with CCRT only (96.8% vs. 82.3%; <italic>P</italic>&#160;=&#160;0.001; <xref rid="F0001">Figure 1A</xref>). The 5-year DMFS was significantly superior in CCRT plus NTZ treated patients than those treated with CCRT only (90.3% vs. 80.6%; <italic>P&#160;</italic>=&#160;0.012; <xref rid="F0001">Figure 1B</xref>). Similarly, the 5-year PFS was significantly higher in CCRT plus NTZ treated patients than those treated with CCRT only (83.9% vs. 71.0%; <italic>P&#160;</italic>=&#160;0.006; <xref rid="F0001">Figure 1C</xref>). There were trends towards improved LRRFS for the addition of NTZ over CRRT only, though no associated difference in LRRFS was observed between both arms (90.3% vs. 88.7%; <italic>P</italic>&#160;=&#160;0.234; <xref rid="F0001">Figure 1D</xref>). Consistent with univariate analysis, multivariate analysis showed that adding NTZ to CCRT was a favorable prognostic factor for OS ([hazard ratio (HR), 0.31; 95% confidence interval (CI), 0.02&#8211;0.71; <italic>P&#160;</italic>=&#160;0.027), DMFS (HR, 0.45; 95% CI, 0.13&#8211;0.77; <italic>P&#160;</italic>=&#160;0.034), and PFS (HR, 0.38; 95% CI, 0.11&#8211;0.89; <italic>P&#160;</italic>=&#160;0.041) (<xref rid="T0002">Table 2</xref>).<table-wrap id="T0002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1080/15384047.2018.1491501-T0002</object-id><label>Table 2.</label><caption><p>Multivariate analysis of treatment regimen status and other prognostic factors for treatment outcomes.</p></caption><!--OASIS TABLE HERE--><table-wrap-foot><fn><p><bold>Abbreviations</bold>: OS, overall survival; DMFS, distant metastasis-free survival; PFS, progression-free survival; LRFFS, locoregional relapse-free survival; NS, not significant.</p></fn></table-wrap-foot></table-wrap>
<fig id="F0001" fig-type="figure" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1080/15384047.2018.1491501-F0001</object-id><label>Figure 1.</label><caption><p>Kaplan-Meier curves of (A) overall survival, (B) distant metastasis-free survival, (C) progression-free survival and (D) locoregional relapse-free survival curves for the CCRT plus nimotuzumab arm versus CCRT arm.</p><p specific-use="attrib"><italic>Abbreviation</italic>: CCRT, concurrent chemoradiotherapy; HR, hazard ratio; CI, confidence interval.</p></caption><graphic specific-use="web-only" content-type="color" xlink:href="kcbt-19-12-1491501-g001"/></fig></p></sec><sec id="S0003-S2004"><title>Acute toxicities</title><p><xref rid="T0003">Table 3</xref> displays the treatment toxicities of each arm. The most frequently observed toxicity was oral mucositis. The rates of grade 3&#8211;4 mucositis was 25.8% in CCRT plus NTZ group, and 19.4% in CCRT only group (<italic>P</italic>&#160;=&#160;0.59). No significant differences in hematology parameters, dermatitis, nausea, vomiting, xerostomia, nephrotoxicity or neurotoxicity were found between the two arms (all <italic>P</italic>&#160;&gt;&#160;0.05). Overall, treatment toxicities during radiotherapy were well-tolerated, and no treatment-related deaths occurred in either arm.<table-wrap id="T0003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1080/15384047.2018.1491501-T0003</object-id><label>Table 3.</label><caption><p>Grade 3&#8211;4 adverse events during radiotherapy.</p></caption><!--OASIS TABLE HERE--><table-wrap-foot><fn><p>*p values were calculated with the &#967;<sup>2</sup> test.</p></fn></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="S0004"><title>Discussion</title><p>This is the first assessment of the clinical outcomes of LA-NPC treated patients with standard CCRT regimen plus NTZ in comparison to CCRT treated patients only. To balance the baseline characteristics of the two arms, a propensity score-matched method was applied. In comparison to CCRT treated patients only, CCRT plus NTZ was statistically associated with superior OS, DMFS, and PFS. Strikingly, NTZ addition to the standard CCRT regimen did not increase acute toxicities.</p><p>EGFR has a major part in tumorigenesis and survival of cancer cells. Several studies<sup><xref rid="CIT0009">9</xref>,<xref rid="CIT0019">19</xref>,<xref rid="CIT0020">20</xref></sup> have demonstrated high EGFR expression is associated with an increased treatment resistance, elevated aggressive phenotype, and poorer prognosis in NPC. EGFR-blocking monoclonal antibodies may potentially exert encouraging effects in LA-NPC. Liu et al.<sup><xref rid="CIT0021">21</xref></sup> examined 42 cases of LA-NPC treated with NTZ plus CCRT. The follow-up median was twenty-five months (ranging 7&#8211;44&#160;months), where only two patients had died by last follow-up. Recently, a preliminary clinical trial<sup><xref rid="CIT0011">11</xref></sup> of 23 patients with LA-NPC treated with CCRT plus NTZ reported an estimated 2-year OS rate of up to 95.0%. Consistent with these studies, we also found adding NTZ to CCRT resulted in encouraging survival outcomes in LA-NPC. Moreover, compared to CCRT only, including NTZ to CCRT was significantly associated with improved survival. This information suggest that combined NTZ with CCRT could maximize survival in LA-NPC patients compared to patients taking CCRT only.</p><p>Previous literature reported 90% control rates for NPC when using IMRT in combination with systematic chemotherapy even in patients presenting with LA-NPC.<sup><xref rid="CIT0022">22</xref>,<xref rid="CIT0023">23</xref></sup> As a result of recent advances in IMRT, there was no observed significant difference in 5-year LRRFS (90.3% vs. 88.7%, <italic>P</italic>&#160;=&#160;0.704) between the two arms. This seems reasonable, as IMRT provides excellent locoregional control,<sup><xref rid="CIT0024">24</xref>,<xref rid="CIT0025">25</xref></sup> and concurrent chemotherapy has been confirmed to improve locoregional control.<sup><xref rid="CIT0026">26</xref>,<xref rid="CIT0027">27</xref></sup> Collectively, these effects would limit the actual benefit of NTZ on LRRFS.</p><p>In the current study, the rate of grade 3&#8211;4 mucositis was comparable between patients receiving CCRT plus NTZ (25.8%) and patients receiving CCRT only (19.4%). A recent retrospective analysis by Liu and colleagues<sup><xref rid="CIT0021">21</xref></sup> also concluded NTZ could be safely combined with CCRT for treatment of LA-NPC. However, Huang et al.<sup><xref rid="CIT0012">12</xref></sup> reported 34.8% of patients receiving CCRT plus NTZ experienced grade 3 to 4 mucositis. These inconsistencies could be due to obvious differences between chemotherapy regimens, where only patients receiving concurrent chemotherapy consisting of cisplatin (100&#160;mg/m<sup>2</sup>) every three weeks or cisplatin (40&#160;mg/m<sup>2</sup>) weekly were eligible for the current study. However, the study by Huang et al.<sup><xref rid="CIT0012">12</xref></sup> included patients who received more intensive concurrent chemotherapy regimens (75&#160;mg/m<sup>2</sup> docetaxel and 80&#160;mg/m<sup>2</sup> nedaplatin), which may have increased the incidence of mucositis during radiotherapy.</p><p>Nonetheless, we must note inherent limitations in the present study. First, this was a single-center observational study, and the number of patients who received CCRT plus NTZ was relatively low. We expect promising results will soon be available from the phase III clinical trial of NTZ in combination with chemoradiation for LA-NPC, even though this study is ongoing but not recruiting participants (ClinicalTrials. gov: NCT01074021). Second, we failed to incorporate data on plasma Epstein&#8211;Barr Virus (EBV) DNA, where prior studies demonstrated strong prediction for NPC survival.<sup><xref rid="CIT0028">28</xref>,<xref rid="CIT0029">29</xref></sup> Further studies are urgently required to identify the individual patients who may benefit most from CCRT plus NTZ based on other biomarkers such as plasma EBV DNA, EGFR status or <italic>K-ras</italic> (kirsten rat sarcoma) gene levels before treatment, especially as NTZ is more expensive than conventional treatment.</p><p>In summary, including NTZ in addition to standard CCRT regimen is more effective for extending survival in LA-NPC patients in comparison to CCRT only. Additionally, CCRT plus NTZ was well-tolerated and did not increase acute toxicities. However, a prospective randomized clinical trial is required to validate the superiority of CCRT plus NTZ compared to CCRT only in LA-NPC.</p></sec></body><back><sec id="S0005"><title>Abbreviations</title><p><table-wrap id="UT0001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1080/15384047.2018.1491501-UT0001</object-id><!--OASIS TABLE HERE--></table-wrap></p></sec><sec id="S0006"><title>Conflict of Interest</title><p>Conflict of interest relevant to this article was not reported.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bray</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Pisani</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Parkin</surname><given-names>DM.</given-names></name></person-group>
<source>Cancer incidence, mortality and prevalence worldwide</source>. <edition>2.0</edition>
<publisher-loc>Lyon</publisher-loc>: <publisher-name>IARC Press</publisher-name>; <year>2004</year>.</mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torr e</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Bray</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lortet-Tieulent</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group>
<article-title>Global cancer statistics, 2012</article-title>. <source>CA Cancer J Clin</source>. <year>2015</year>; <volume>65</volume>:<fpage>87</fpage>&#8211;<lpage>108</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21262</pub-id>.<pub-id pub-id-type="pmid">25651787</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>WF</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>LZ</given-names></name>, <name name-style="western"><surname>Mao</surname><given-names>YP</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>GQ</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J</given-names></name></person-group>
<article-title>Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation</article-title>. <source>Chin J Cancer</source>. <year>2012</year>;<volume>31</volume>(<issue>12</issue>):<fpage>579</fpage>&#8211;<lpage>587</lpage>. doi:<pub-id pub-id-type="doi">10.5732/cjc.012.10095</pub-id>.<pub-id pub-id-type="pmid">22854064</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>Internet National Comprehensive Cancer Network</collab></person-group>
<article-title>NCCN Guidelines: head and neck cancers</article-title>; <source>Version 2</source>.<year>2013</year>
<ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp">http://www.nccn.org/professionals/physician_gls/f_guidelines.asp</ext-link>.</mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Sze</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Au</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Leung</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Leung</surname><given-names>TW</given-names></name>, <name name-style="western"><surname>Chua</surname><given-names>DT</given-names></name>, <name name-style="western"><surname>Zee</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Law</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Teo</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Tung</surname><given-names>SY</given-names></name>, et al</person-group>
<article-title>Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>2005</year>; <volume>61</volume>:<fpage>1107</fpage>&#8211;<lpage>1116</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijrobp.2004.07.702</pub-id>.<pub-id pub-id-type="pmid">15752890</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>BB</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>EP</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>AT</given-names></name></person-group>
<article-title>Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions</article-title>. <source>Cancer Sci</source>. <year>2008</year>;<volume>99</volume>(<issue>7</issue>):<fpage>1311</fpage>&#8211;<lpage>1318</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1349-7006</pub-id>.<pub-id pub-id-type="pmid">18498420</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciardiello</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Tortora</surname><given-names>G</given-names></name></person-group>
<article-title>A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor</article-title>. <source>Clin Cancer Res</source>. <year>2001</year>; <volume>7</volume>:<fpage>2958</fpage>&#8211;<lpage>2970</lpage>.<pub-id pub-id-type="pmid">11595683</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendelsohn</surname><given-names>J</given-names></name></person-group>
<article-title>Targeting the epidermal growth factor receptor for cancer therapy</article-title>. <source>J Clin Oncol</source>. <year>2002</year>; <volume>20</volume>:<fpage>1S</fpage>&#8211;<lpage>13S</lpage>.<pub-id pub-id-type="pmid">12235219</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>ZX</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>JY</given-names></name></person-group>
<article-title>p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study</article-title>. <source>Oncology Letters</source>. <year>2015</year>; <volume>9</volume>:<fpage>113</fpage>&#8211;<lpage>118</lpage>. doi:<pub-id pub-id-type="doi">10.3892/ol.2014.2631</pub-id>.<pub-id pub-id-type="pmid">25435943</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ang</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Rosenthal</surname><given-names>DI</given-names></name>, <name name-style="western"><surname>Nguyen-Tan</surname><given-names>PF</given-names></name>, <name name-style="western"><surname>Sherman</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Weber</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Galvin</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Bonner</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>J</given-names></name>, <name name-style="western"><surname>El-Naggar</surname><given-names>AK</given-names></name>, et al</person-group>
<article-title>Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522</article-title>. <source>J Clin Oncol</source>. <year>2014</year>;<volume>32</volume>(<issue>27</issue>):<fpage>2940</fpage>&#8211;<lpage>2950</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2013.53.5633</pub-id>.<pub-id pub-id-type="pmid">25154822</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talavera</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Friemann</surname><given-names>R</given-names></name>, <name name-style="western"><surname>G&#243;mez-Puerta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Martinez-Fleites</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Garrido</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Rabasa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>L&#243;pez-Requena</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pupo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Johansen</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>S&#225;nchez</surname><given-names>O</given-names></name>, et al</person-group>
<article-title>Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation</article-title>. <source>Cancer Research</source>. <year>2009</year>; <volume>69</volume>:<fpage>5851</fpage>&#8211;<lpage>5859</lpage>. doi:<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-4518</pub-id>.<pub-id pub-id-type="pmid">19584289</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>FZ</given-names></name>, <name name-style="western"><surname>Zou</surname><given-names>QZ</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>LY</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>XP</given-names></name>, <name name-style="western"><surname>Tai</surname><given-names>GM</given-names></name>, et al</person-group>
<article-title>Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial</article-title>. <source>Oncotarget</source>. <year>2017</year>;<volume>8</volume>(<issue>2</issue>):<fpage>2457</fpage>&#8211;<lpage>2465</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.13899</pub-id>.<pub-id pub-id-type="pmid">27974693</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>XL</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>GQ</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Mao</surname><given-names>YP</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name></person-group>
<article-title>Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis</article-title>. <source>Chin J Cancer</source>. <year>2017</year>;<volume>36</volume>(<issue>1</issue>):<fpage>26</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40880-017-0195-6</pub-id>.<pub-id pub-id-type="pmid">28264724</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>ICRU report</collab></person-group>
<source>Vol. 62: prescribing, recording, and reporting photon beam therapy</source>. <publisher-loc>Maryland</publisher-loc>: <publisher-name>International Commission on Radiation Units and Measurements</publisher-name>; <year>1999</year>.</mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>ICRU Report</collab></person-group>
<source>Vol. 83: prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT)</source>. <publisher-loc>Maryland</publisher-loc>: <publisher-name>International Commission on Radiation Units and Measurements</publisher-name>; <year>2010</year>.</mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Agostino</surname><given-names>RB</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group</article-title>. <source>Stat Med</source>. <year>1998</year>; <volume>17</volume>:<fpage>2265</fpage>&#8211;<lpage>2281</lpage>. doi:<pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(19981015)17:19&lt;2265::AID-SIM918&gt;3.0.CO;2-B</pub-id>.<pub-id pub-id-type="pmid">9802183</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Meier</surname><given-names>P</given-names></name></person-group>
<article-title>Nonparametric estimation from incomplete observation</article-title>. <source>J Am Stat Assoc</source>. <year>1958</year>; <volume>53</volume>:<fpage>457</fpage>&#8211;<lpage>481</lpage>. doi:<pub-id pub-id-type="doi">10.1080/01621459.1958.10501452</pub-id>.</mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>DR</given-names></name></person-group>
<article-title>Regression models and life tables</article-title>. <source>J Roy Stat Soc B</source>. <year>1972</year>; <volume>34</volume>:<fpage>187</fpage>&#8211;<lpage>220</lpage>.</mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>L</given-names></name></person-group>
<article-title>Epidermal growth factor receptor could play a prognostic role to predict the outcome of nasopharyngeal carcinoma: A meta-analysis</article-title>. <source>Cancer Biomark</source>. <year>2014</year>;<volume>14</volume>(<issue>4</issue>):<fpage>267</fpage>&#8211;<lpage>277</lpage>. doi:<pub-id pub-id-type="doi">10.3233/CBM-140401</pub-id>.<pub-id pub-id-type="pmid">24934370</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mei</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>G</given-names></name></person-group>
<article-title>Prognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: a meta-analysis</article-title>. <source>Head Neck</source>. <year>2014</year>;<volume>36</volume>(<issue>10</issue>):<fpage>1508</fpage>&#8211;<lpage>1516</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hed.23481</pub-id>.<pub-id pub-id-type="pmid">23996630</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>ZG</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>YF</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H</given-names></name></person-group>
<article-title>Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis</article-title>. <source>Oncotarget</source>. <year>2016</year>;<volume>7</volume>(<issue>17</issue>):<fpage>24429</fpage>&#8211;<lpage>24435</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.8225</pub-id>.<pub-id pub-id-type="pmid">27016412</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>KY</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>G</given-names></name></person-group>
<article-title>A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma</article-title>. <source>Radiother Oncol</source>. <year>2012</year>;<volume>104</volume>(<issue>3</issue>):<fpage>286</fpage>&#8211;<lpage>293</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.radonc</pub-id>.<pub-id pub-id-type="pmid">22995588</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>MX</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Zou</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>You</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hua</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J</given-names></name>, et al</person-group>
<article-title>Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up</article-title>. <source>Eur J Cancer</source>. <year>2015</year>;<volume>51</volume>(<issue>17</issue>):<fpage>2587</fpage>&#8211;<lpage>2595</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejca.2015.08.006</pub-id>.<pub-id pub-id-type="pmid">26318726</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Garden</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Straube</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Glisson</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bosch</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Morrison</surname><given-names>WH</given-names></name>, <name name-style="western"><surname>Quivey</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Thorstad</surname><given-names>W</given-names></name>, et al</person-group>
<article-title>Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225</article-title>. <source>J Clin Oncol</source>. <year>2009</year>;<volume>27</volume>(<issue>22</issue>):<fpage>3684</fpage>&#8211;<lpage>3690</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2008.19.9109</pub-id>.<pub-id pub-id-type="pmid">19564532</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Quivey</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Sultanem</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Poon</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Akazawa</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Akazawa</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Weinberg</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>KK</given-names></name></person-group>
<article-title>Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>2002</year>;<volume>53</volume>(<issue>1</issue>):<fpage>12</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">12007936</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aw</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wh</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sy</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Dt</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chappell</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Siu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wm</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tw</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Js</surname><given-names>S</given-names></name>, et al., <collab>Nasopharyngeal Cancer Study Group</collab></person-group>
<article-title>Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group</article-title>. <source>J Clin Oncol</source>. <year>2005</year>; <volume>23</volume>: <fpage>6966</fpage>&#8211;<lpage>6975</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2004.00.7542</pub-id>.<pub-id pub-id-type="pmid">16192584</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blanchard</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Marguet</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Leclercq</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wt</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J</given-names></name>, <name name-style="western"><surname>At</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Py</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Benhamou</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>G</given-names></name>, et al., <collab>MAC-NPC Collaborative Group</collab></person-group>
<article-title>Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis</article-title>. <source>Lancet Oncol</source>. <year>2015</year>;<volume>16</volume>(<issue>6</issue>):<fpage>645</fpage>&#8211;<lpage>655</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(15)70126-9</pub-id>.<pub-id pub-id-type="pmid">25957714</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>WY</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>KY</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Jan</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>RS</given-names></name></person-group>
<article-title>Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>350</volume>(<issue>24</issue>):<fpage>2461</fpage>&#8211;<lpage>2470</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa032260</pub-id>.<pub-id pub-id-type="pmid">15190138</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>YM</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>LY</given-names></name>, <name name-style="western"><surname>Leung</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Lam</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>PJ</given-names></name></person-group>
<article-title>Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA</article-title>. <source>Cancer Res</source>. <year>2000</year>;<volume>60</volume>(<issue>24</issue>):<fpage>6878</fpage>&#8211;<lpage>6881</lpage>.<pub-id pub-id-type="pmid">11156384</pub-id></mixed-citation></ref></ref-list></back></article>